Anticalmodulin autoantibody in liver diseases: A new antibody against a cytoskeleton‐related protein

Yusei Ikeda, Gotaro Toda, Naoaki Hashimoto, Shin‐Ichi Aotsuka, Ryuichi Yokohari, Toshiyuki Maruyama, Hiroshi Oka – 1 March 1987 – An ELISA has been developed for detection of auto‐antibodiees against calmodulin. There was a significantly increased frequency (63.1%) of autoantibodies against calmodulin in 103 patients with chronic liver diseases as compared to that (30%) of patients with systemic lupus erythematosus and to that (6.9%) of normal subjects (p < 0.01).

Stimulatory effects of ethanol on amino acid transport by rat fetal hepatocytes

David W. Heitman, Teri A. Frosto, Steven Schenker, George I. Henderson – 1 March 1987 – Previous studies have indicated that acute, and especially chronic, maternal ethanol consumption can depress placental uptake of various amino acids. Since the fetal cell itself represents a second barrier to nutrients, one which may be altered by ethanol exposure, the effects of ethanol on amino acid net uptake by rat fetal hepatocytes was addressed. The present study determined that ethanol stimulated amino acid net uptake by fetal hepatocytes grown in monolayer culture.

Overnight salivary caffeine clearance: A liver function test suitable for routine use

Gerhard Jost, Axel Wahlländer, Ursula Von Mandach, Rudolf Preisig – 1 March 1987 – The feasibility of measuring caffeine clearance from saliva (SCI) was assessed in ambulatory patients with liver disease and in a control group, and the results were compared with quantitative liver function tests. For this purpose, the subjects were given 280 mg caffeine p.o. in decaffeinated coffee powder between noon and 4 p.m., and caffeine concentrations were measured in saliva (using an enzyme immunoassay) before bedtime and upon arising. In the cirrhotics (n = 29), SCI was 0.58 ± S.D.

Le Veen vs. Denver peritoneovenous shunts: Inadequate numbers or technique?

Laurence M. Blendis, Robert H. Lund – 1 March 1987 – Peritoneovenous shunts (PVSs) have provided salutary effects on medically recalcitrant ascites, functional renal impairment, nutritional derangements, ventilatory embarrassment, and locomotion potential in patients with cirrhosis. While the LeVeen (LPVS) and Denver (DPVS) PVSs are most frequently implanted in such patients, postoperative complications of bleeding gastroesophageal varices, sepsis, and shunt occlusion occur with notable frequency.

Encapsulated hepatocellular carcinoma in the absence of cirrhosis: A favorable prognosis

Fenton Schaffner – 1 March 1987 – Clinicopathological features were studied in 41 patients with histology‐proven hepatocellular carcinoma without cirrhosis. Of these, 13 (31.7%) were positive for hepatitis B virus surface antigen (HBsAg) and 28 were negative. Twenty‐six of 28 (92.9%) HBsAg negative cases had anticore antibody (anti‐HBc) of low titres. The age of patients at the time of diagnosis of hepatocellular carcinoma was significantly younger in the HBsAg positive cases compared with the negative.

The diagnosis of hepatic metastases: Converting a chance into a choice

Klemens B. Meyer, Jerome P. Kassirer – 1 March 1987 – Clinicians frequently perform tests to determine whether patients have liver metastases. Optimal use of a laboratory test requires that the clinician know the test's operating characteristics (its sensitivity and specificity) and have an estimate of the pretest probability that disease is present. We have surveyed studies that examined the value of four biochemical and three imaging tests in establishing a diagnosis of hepatic metastases in patients who underwent an invasive procedure to establish the presence or absence of disease.

Accumulation of 7α‐hydroxy‐4‐cholesten‐3‐one and cholesta‐4,6‐dien‐3‐one in patients with cerebrotendinous xanthomatosis: Effect of treatment with chenodeoxycholic acid

Ingemar Björkhem, Sverre Skrede, Marie S. Buchmann, Cara East, Scott Grundy – 1 March 1987 – Evidence was recently presented that an essential part of the accumulation of cholestanol in patients with cerebrotendinous xanthomatosis is due to acceleration of a novel pathway, involving 7α‐hydroxylated intermediates in bile acid biosynthesis as precursors (J. Clin. Invest. 1985; 75:448–456). Such intermediates accumulate in patients with cerebrotendinous xanthomatosis due to lack of the mitochondrial 26‐hydroxylase involved in the major pathway for bile acid biosynthesis.

Subscribe to